Oncogenic pathways in hereditary and sporadic breast cancer

Maturitas

Volumn 49, Issue 1, 2004, Pages 34-43

  Kenemans, P ^a   Verstraeten, R A ^a   Verheijen, R H M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Breast cancer; Hereditary; Tumorigenesis

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CHECKPOINT KINASE 2; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; RETINOBLASTOMA PROTEIN; UVOMORULIN;

APOPTOSIS; BREAST CANCER; BREAST HYPERPLASIA; CANCER GROWTH; CANCER RISK; CANCER STAGING; CARCINOGENESIS; CARCINOGENICITY; CELL ADHESION; CELL INVASION; CHROMOSOME ABERRATION; CHROMOSOME DELETION; COMPARATIVE GENOMIC HYBRIDIZATION; CONFERENCE PAPER; DNA FINGERPRINTING; DNA MICROARRAY; DNA REPAIR; FAMILIAL CANCER; FLUORESCENCE IN SITU HYBRIDIZATION; GENE ACTIVATION; GENE DELETION; GENE EXPRESSION; GENE INACTIVATION; GENETIC SUSCEPTIBILITY; HETEROZYGOSITY LOSS; HUMAN; METHYLATION; MICROSATELLITE INSTABILITY; MOLECULAR MECHANICS; ONCOGENE; PLOIDY; POINT MUTATION; PROMOTER REGION; REGULATOR GENE; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MODELS, GENETIC; MUTATION;

EID: 4444339665     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2004.06.005     Document Type: Conference Paper

References (79)

1. Beckmann W.M., Niederacher D., Schnürch H.-G., Gusterson B.A., Bender H.G. Multistep carcinogenesis of breast cancer and tumour heterogeneity. J. Mol. Med. 75:1997;429-439
2. Wooster R., Weber B.L. Breast and ovarian cancer. N. Engl. J. Med. 348:2003;2339-2347
3. Dunning A.M., Healey C.S., Pharoah P.D., Teare M.D., Ponder B.A., Easton D.F. A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 8:1999;843-854
4. Clemons M., Goss P. Estrogen and the risk of breast cancer. N. Engl. J. Med. 344:2001;276-285
5. Osin P.P., Anbazhagan R., Bartkova J., Nathan B., Gusterson B.A. Breast development gives insights into breast disease. Histopathology. 33:1998;275-283
6. O'Connell P. Genetic and cytogenetic analyses of breast cancer yield different perspectives of a complex disease. Breast Cancer Res. Treat. 78:2003;347-357
7. Balogh G.A., Russo I.H., Russo J. Mutations in mismatch repair genes are involved in the neoplastic transformation of human breast epithelial cells. Int. J. Oncol. 23:2003;411-419
8. Patterson A.H., McManus D.T., Maxwell P. Detection of chromosomal numerical abnormalities in clinical breast tumour fine-needle aspirations by fluorescence in situ hybridisation (FISH): refinement of a method. Br. J. Biomed. Sci. 55:1998;2-7
9. Tong D., Schuster E., Czerwenka K., Leodolter S., Zeillinger R. Loss of heterozygosity on chromosome 13q: suggestion of a candidate tumor suppressor gene in sporadic breast cancer. Breast Cancer Res. Treat. 83:2004;143-148
10. Bürger H., Schmidt H., Beckmann A., Zänker K.S., Böckner W., Brandt H. Genetic characterisation of invasive breast cancer - a comparison of CGH and PCR-based multiplex microsatellite analysis. J. Clin. Pathol. 54:2001;836-840
11. Nass S.J., Dickson R.B. Defining a role for c-Myc in breast tumorigenesis. Breast Cancer Res. Treat. 44:1997;1-22
12. Ormandy C.J., Musgrove E.A., Hui R., Daly R.J., Sutherland R.L. Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res. Treat. 78:2003;323-335
13. Hosokawa Y., Arnold A. Mechanism of cyclin D1 (CCND1, PRAD1) overexpression in human cancer cells: analysis of allele-specific expression. Genes Chromosomes Cancer. 22:1998;66-71
14. Barnes D.M., Gillett C.E. Cyclin D1 in breast cancer. Breast Cancer Res. Treat. 52:1998;1-15
15. Steeg P.S., Zhou Q. Cyclins and breast cancer. Breast Cancer Res. Treat. 52:1998;17-28
16. Miles D.W., Harris W.H., Gillett C.E., Smith P., Barnes D.M. Effect of c-erbB(2) and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil. Int. J. Cancer. 84:1999;354-359
17. Fioravanti L., Cappelletti V., Coradini D., et al. Int-2 oncogene amplification and prognosis in node-negative breast carcinoma. Int. J. Cancer. 74:1997;620-624
18. An H.X., Niederacher D., Dominik S.I., et al. Int-2 and c-erbB-2 gene amplification detected in 70 frozen human breast carcinomas by quantitative polymerase chain reaction. Anticancer Res. 17:1997;3133-3136
19. Earp H.S. 3rd, Calvo B.F., Sartor C.I. The EGF receptor family - multiple roles in proliferation, differentiation, and neoplasia with an emphasis on HER4. Trans. Am. Clin. Climatol. Assoc. 114:2003;315-333
20. Druckmann R., Rohr U.D. IGF-1 in gynaecology and obstetrics: update 2002. Maturitas. 41(S1):2002;S65-S83
21. Sachdev D., Yee D. The IGF system and breast cancer. Endocr. Relat. Cancer. 8:2001;197-209
22. Barcellos-Hoff M.H. Latency and activation in the control of TGF-beta. J. Mammary Gland. Biol. Neoplasia. 1:1996;353-363
23. Miki Y., Swensen J., Shattuck-Eidens D., et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 266:1994;66-71
24. Cable P.L., Wilson C.A., Calzone F.J., et al. Novel consensus DNA-binding sequence for BRCA1 protein complexes. Mol. Carcinog. 38:2003;85-96
25. Jhanwar-Uniyal M. BRCA1 in cancer, cell cycle and genomic stability. Front Biosci. 8:2003;S1107-S1117
26. Venkitaraman A.R. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell. 108:2002;171-182
27. Lambie H., Miremadi A., Pinder S.E., et al. Prognostic significance of BRCA1 expression in sporadic breast carcinomas. J. Pathol. 200:2003;207-213
28. Kerr P., Ashworth A. New complexities for BRCA1 and BRCA2. Curr. Biol. 11:2001;R668-R676
29. Vidarsson H., Mikaelsdottir E.K., Rafnar T., et al. BRCA1 and BRCA2 bind Stat5a and suppress its transcriptional activity. FEBS Lett. 532:2002;247-252
30. Lerebours F., Lidereau R. Molecular alterations in sporadic breast cancer. Crit. Rev. Oncol. Hematol. 44:2002;121-141
31. Ko L.J., Prives C. p53: puzzle and paradigm. Genes Dev. 10:1996;1054-1072
32. Sigal A., Rotter V. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res. 60:2000;6788-6793
33. Gasco M., Yulug I.G., Crook T. TP53 mutations in familial breast cancer: functional aspects. Hum. Mutat. 21:2003;301-306
34. Santibanez-Koref M.F., Birch J.M., Hartley A.L., et al. p53 germline mutations in Li-Fraumeni syndrome. Lancet. 338:1991;1490-1491
35. Law J.C., Strong L.C., Chidambaram A., Ferrell R.E. A germ line mutation in exon 5 of the p53 gene in an extended cancer family. Cancer Res. 51:1991;6385-6387
36. Varley J.M. Germline TP53 mutations and Li-Fraumeni syndrome. Hum. Mutat. 21:2003;313-320
37. Sherr C.J. Cancer cell cycles. Science. 274:1996;672-677
38. Wang A., Schneider-Broussard R., Kumar A.P., MacLeod M.C., Johnson D.G. Regulation of BRCA1 expression by the Rb-E2F pathway. J. Biol. Chem. 275:2000;4532-4536
39. Ueda K., Nishijima M., Inui H., et al. Infrequent mutations in the PTEN/MMAC1 gene among primary breast cancers. Jpn. J. Cancer Res. 89:1998;17-21
40. Rouse J., Jackson S.P. Interfaces between the detection, signalling, and repair of DNA damage. Science. 297:2002;547-551
41. Myung K., Datta A., Kolodner R.D. Suppression of spontaneous chromosomal rearrangements by S phase checkpoint functions in Saccharomyces cerevisiae. Cell. 104:2001;397-408
42. Meijers-Heijboer H., van den Ouweland A., Klijn J., et al. Low-penetrance susceptibility to breast cancer due to CHEK2(,)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat. Genet. 31:2002;55-59
43. Vahteristo P., Bartkova J., Eerola H., et al. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am. J. Hum. Genet. 71:2002;432-438
44. Berx G., Cleton-Jansen A.M., Nollet F., et al. E-Cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J. 14:1995;6107-6115
45. Makin G., Dive C. Recent advances in understanding apoptosis: new therapeutic opportunities in cancer chemotherapy. Trends Mol. Med. 9:2003;251-255
46. Liu W., Bulgaru A., Haigentz M., Stein C.A., Perez-Soler R., Mani S. The BCL2-family of protein ligands as cancer drugs: the next generation of therapeutics. Curr. Med. Chem. Anticancer Agents. 3:2003;217-223
47. Kenemans P., Bosman A. Breast cancer and post-menopausal hormone therapy. Best Pract. Res. Clin. Endocrinol. Metab. 17:2003;123-137
48. Liehr J.G. Dual role of oestrogens as hormones and pro-carcinogens: tumour initiation by metabolic activation of oestrogens. Eur. J. Cancer Prev. 6:1997;3-10
49. Kuiper G.G., Enmark E., Pelto-Huikko M., Nilsson S., Gustafsson J.A. Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. USA. 93:1996;5925-5930
50. Hayashi S.I., Eguchi H., Tanimoto K., et al. The expression and function of estrogen receptor alpha and beta in human breast cancer and its clinical application. Endocr. Relat. Cancer. 10:2003;193-202
51. Cullen R., Maguire T.M., McDermott E.W., Hill A.D., O'Higgins N.J., Duffy M.J. Studies on oestrogen receptor-alpha and -beta mRNA in breast cancer. Eur. J. Cancer. 37:2001;1118-1122
52. Richer J.K., Jacobsen B.M., Manning N.G., Abel M.G., Wolf D.M., Horwitz K.B. Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. J. Biol. Chem. 277:2002;5209-5218
53. Sledge G.W. Jr., Miller K.D. Exploiting the hallmarks of cancer: the future conquest of breast cancer. Eur. J. Cancer. 39:2003;1668-1675
54. Boudreau N., Myers C. Breast cancer-induced angiogenesis: multiple mechanisms and the role of the microenvironment. Breast Cancer Res. 5:2003;140-146
55. Yoshiji H., Gomez D.E., Shibuya M., Thorgeirsson U.P. Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res. 56:1996;2013-2016
56. Relf M., LeJeune S., Scott P.A., et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 57:1997;963-969
57. Fukumura D., Xavier R., Sugiura T., et al. Tumor induction of VEGF promoter activity in stromal cells. Cell. 94:1998;715-725
58. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 61:1990;759-767
59. Tirkkonen M., Johannsson O., Agnarsson B.A., et al. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res. 57:1997;1222-1227
60. Bürger H., Otterbach F., Simon R., et al. Comparative genomic hybridization of ductal carcinoma in situ of the breast-evidence of multiple genetic pathways. J. Pathol. 187:1999;396-402
61. Bürger H., Simon R., Schäfer K.-L., et al. Genetic relationship of lobular carcinoma in situ, ductal carcinoma in situ and invasive carcinoma of the breast. J. Clin. Pathol.: Mol. Pathol. 53:2000;118-121
62. Bürger H., Mommers E.C., Littman R., et al. Ductal invasive G2 and G3 carcinomas of the breast are the end stage of at least two different lines of genetic evolution. J. Pathol. 194:2001;165-170
63. Weinstat S.D., Merino M.J., Manrow R.E., et al. Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nat. Med. 1:1995;1257-1260
64. Done S.J., Arneson N.C., Ozcelik H., Redston M., Andrulis I.L. p53 mutations in mammary ductal carcinoma in situ but not in epithelial hyperplasias. Cancer Res. 58:1998;785-789
65. Quinn C.M., Ostrowski J.L., Harkins L., Rice A.J., Loney D.P. Loss of bcl-2 expression in ductal carcinoma in situ of the breast relates to poor histological differentiation and to expression of p53 and c-erbB-2 proteins. Histopathology. 33:1998;531-536
66. Gupta S.K., Douglas J.A., Jasani B., Morgan J.M., Pignatelli M., Mansel R.E. E-Cadherin (E-cad) expression in duct carcinoma in situ (DCIS) of the breast. Virchows Arch. 430:1997;23-28
67. Richard F., Pacyna-Gengelbach M., Schluns K., et al. Patterns of chromosomal imbalances in invasive breast cancer. Int. J. Cancer. 89:2000;305-310
68. Kuukasjarvi T., Tanner M., Pennanen S., Karhu R., Kallioniemi O.P., Isola J. Genetic changes in intraductal breast cancer detected by comparative genomic hybridization. Am. J. Pathol. 150:1997;1465-1471
69. van't Veer L.J., Dai H., van de Vijver M.J., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 415:2002;530-536
70. van de Vijver M.J., He Y.D., van't Veer L.J., et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347:2002;1999-2009
71. Sørlie T., Tibshirani R., Parker J., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. USA. 100:2003;8418-8423
72. Fraser J.A., Reeves J.R., Stanton P.D., et al. A role for BRCA1 in sporadic breast cancer. Br. J. Cancer. 88:2003;1263-1270
73. Rosen E.M., Fan S., Pestell R.G., Goldberg I.D. BRCA1 gene in breast cancer. J. Cell Physiol. 196:2003;19-41
74. Dobrovic A., Simpfendorfer D. Methylation of the BRCA1 gene in sporadic breast cancer. Cancer Res. 57:1997;3347-3350
75. Hughes-Davies L., Huntsman D., Ruas M., et al. EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell. 115:2003;523-535
76. King M.C. A novel BRCA2-binding protein and breast and ovarian tumorigenesis. N. Engl. J. Med. 350:2004;1252-1253
77. Mote P.A., Leary J.A., Avery K.A., et al. kConFab Investigators. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A. Genes Chromosomes Cancer. 39:2004;236-248
78. Knudson A.G. Jr. Mutation and cancer: statistical study of retinoblastoma. Proc. Natl. Acad. Sci. USA. 68:1971;820-823
79. Wessels L.F., van Welsem T., Hart A.A., van't Veer L.J., Reinders M.J., Nederlof P.M. Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors. Cancer Res. 62:2002;7110-7117